Clinical trial · Interventional
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT03991962CI-TRIAL-00099663active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of modified FOLFIRINOX followed by stereotactic body radiotherapy (SBRT) in patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC). The primary hypothesis will be to determine if modified FOLFIRINOX followed by SBRT improves progression free survival (PFS) compared to historical controls treated with gemcitabine-based chemotherapy with or without standard fractionated radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mFOLFIRINOX | Drug | — | UNRESOLVED |
| Stereotactic body radiotherapy (SBRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- mFOLFIRINOX followed by SBRT
- description
- Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
- interventionNames
- Drug: mFOLFIRINOX
- Radiation: Stereotactic body radiotherapy (SBRT)
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- 9 months
- description
- Progression-free survival (PFS) at will be judged by CT scan and Response evaluation criteria in solid tumors (RECIST).
Secondary outcomes (4)
- measure
- Radiographic Response
- timeFrame
- Within 21 days of starting study drug
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed pancreatic adenocarcinoma * Borderline resectable pancreatic adenocarcinoma or locally advanced pancreatic adenocarcinoma * No evidence of extrapancreatic disease on diagnostic imaging * No evidence of invasion into the duodenum or stomach, as determined by EGD/EUS * No prior treatment (chemotherapy, biological therapy, or radiotherapy) for pancreatic cancer * No prior treatment with oxaliplatin, irinotecan, fluorouracil, or capecitabine * ECOG Performance Status of 0-1 * No other malignancy within past five years (exceptions include basal cell carcinoma of the skin, cervical carcinoma in situ, and non-metastatic prostate cancer) * No evidence of second malignancy at the time of study entry * No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung * No \> grade 2 sensory peripheral neuropathy * No uncontrolled seizure disorder, active neurological disease, or known CNS disease * No significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment * Not pregnant and not nursing * No other medical condition or reason that, in the opinion of the investigator, would preclude study participation * Laboratory parameters as follows: * Absolute neutrophil count ≥1,500/uL, * Platelet count ≥75,000/uL, * Hemoglobin ≥9 g,/dL, * Creatinine \<1.5 X ULN or estimated GFR \>30 ml/min, * Bilirubin \<1.5 X ULN, * AST and ALT \<3 X ULN, * Negative pregnancy test in women of childbearing potential * Able to be treated with SBRT only at the Smilow New Haven campus * Able to have fiducials placed in the pancreas Exclusion Criteria: * Failing to meet any of the Inclusion Criteria
References
Publications (0)
Data not yet available
No reference posted for this study.